Manzine P.R.
137
Coauthors
13
Documentos
Volumen de publicaciones por año
Cargando gráfico
| Año de publicación | Num. Publicaciones |
|---|---|
| 2018 | 2 |
| 2019 | 4 |
| 2020 | 4 |
| 2021 | 3 |
Publicaciones por áreas de conocimiento
Cargando gráfico
| Área de conocimiento | Num. Publicaciones |
|---|---|
| Farmacología | 7 |
| Neuropsicología | 4 |
| Neurología | 3 |
| Medicamento | 3 |
| Metabolismo | 2 |
| Diabetes | 2 |
| Bioquímica | 1 |
| Medicina interna | 1 |
| Biología molecular | 1 |
| Nutrición | 1 |
Publicaciones por áreas temáticas
Cargando gráfico
| Área temática | Num. Publicaciones |
|---|---|
| Enfermedades | 12 |
| Fisiología humana | 8 |
| Farmacología y terapéutica | 5 |
| Medicina y salud | 4 |
Principales fuentes de datos
| Origen | Num. Publicaciones |
|---|---|
| Scopus | 13 |
| Google Scholar | 0 |
| RRAAE | 0 |
Cargando gráfico
Coautores destacados por número de publicaciones
| Coautor | Num. Publicaciones |
|---|---|
| Antoni Camins | 13 |
| Olloquequi J. | 12 |
| Ettcheto M. | 12 |
| Busquets O. | 11 |
| Folch J. | 10 |
| Auladell C. | 10 |
| Verdaguer E. | 9 |
| Cano A. | 9 |
| Sanchez-Lopez E. | 8 |
| Castro-Torres R.D. | 8 |
Cargando gráfico
Top Keywords
Cargando gráfico
Publicaciones del autor
Alpha-secretase ADAM10 regulation: Insights into Alzheimer’s disease treatment
ReviewAbstract: ADAM (a disintegrin and metalloproteinase) is a family of widely expressed, transmembrane and secretPalabras claves:ADAM10, Alzheimer’s disease, regulation, TreatmentAutores:Antoni Camins, Cominetti M.R., Manzine P.R., Peron R., Vatanabe I.P.Fuentes:scopusMetformin a potential pharmacological strategy in late onset Alzheimer’s disease treatment
ReviewAbstract: Alzheimer’s disease (AD) is one of the most devastating brain disorders. Currently, there are no effPalabras claves:Alzheimer’s disease, AMP activated protein kinase AMPK, Beta amyloid, diabetes mellitus, Insulin Resistance, Metformin, Tau protein hyperphosphorylationAutores:Antoni Camins, Cano A., Ettcheto M., Javan M., Manzine P.R., Olloquequi J., Poor S.R., Sanchez-Lopez E.Fuentes:scopusThe preclinical discovery and development of opicapone for the treatment of Parkinson’s disease
ArticleAbstract: Introduction: Opicapone (OPC) is a well-established catechol-O-methyltransferase (COMT) inhibitor thPalabras claves:dyskinesia, entacapone, Opicapone, Parkinson’s Disease, tolcaponeAutores:Antoni Camins, Auladell C., Busquets O., Cano A., Ettcheto M., Folch J., Manzine P.R., Olloquequi J., Sanchez-Lopez E., Verdaguer E.Fuentes:scopusADAM10 in Alzheimer's disease: Pharmacological modulation by natural compounds and its role as a peripheral marker
ReviewAbstract: Alzheimer's disease (AD) represents a global burden in the economics of healthcare systems. Amyloid-Palabras claves:ADAM10, Alzheimer's disease, Natural compounds, Pharmaceutical, α-SecretaseAutores:Antoni Camins, Busquets O., Cano A., Cominetti M.R., Di Luca M., Endres K., Ettcheto M., Manzine P.R., Marcello E., Olloquequi J., Pelucchi S.Fuentes:scopusEpigallocatechin-3-Gallate (EGCG) Improves Cognitive Deficits Aggravated by an Obesogenic Diet Through Modulation of Unfolded Protein Response in APPswe/PS1dE9 Mice
ArticleAbstract: Epigallocatechin-3-gallate (EGCG), a catechin found in green tea, has been previously investigated fPalabras claves:APPswe/PS1dE9 mice, Cognitive deficits, Epigallocatechin-3-gallate, hippocampus, obesity, unfolded protein responseAutores:Antoni Camins, Auladell C., Busquets O., Cano A., Castro-Torres R.D., Ettcheto M., Folch J., García M.L., Manzine P.R., Olloquequi J., Verdaguer E., Zárate C.B.Fuentes:scopus